SGLT2 Inhibitors as Gerotherapeutics: From Diabetes Medications to Longevity Candidates

In geroscience and preventive medicine, sodium-glucose cotransporter-2 (SGLT2) inhibitors are widely recognized as having among the strongest human clinical trial evidence of any candidate gerotherapeutic [1].

Originally developed as antihyperglycemic agents for Type 2 diabetes, SGLT2 inhibitors—including empagliflozin, dapagliflozin, and canagliflozin—have transformed cardiorenal medicine over the past decade. Large-scale randomized outcome trials repeatedly show that these drugs reduce cardiovascular mortality, heart failure hospitalizations, and chronic kidney disease progression across both diabetic and non-diabetic populations [1].

Because their systemic organ-protective benefits extend far beyond blood glucose control, researchers now evaluate SGLT2 inhibitors for their ability to target the fundamental biological mechanisms of human aging [1, 2].

Here is an evidence-based breakdown of SGLT2 inhibitors: their current clinical indications, biological mechanisms, preclinical lifespan data, human trial evidence, targeted hallmarks of aging, and the research required to establish their role in healthy aging.

1. Current Clinical Indications

SGLT2 inhibitors operate by inhibiting the SGLT2 protein in the proximal convoluted tubules of the kidney. This blocks the reabsorption of glucose and sodium, promoting their excretion in the urine (glucosuria and natriuresis) [1].

Regulatory agencies have approved SGLT2 inhibitors for three primary clinical conditions:

• Type 2 Diabetes Mellitus: Improving glycemic control while lowering blood pressure and promoting modest weight loss [1].

• Heart Failure: Reducing cardiovascular death and heart failure hospitalization in patients with heart failure across the spectrum of ejection fraction—both reduced (HFrEF) and preserved (HFpEF)—regardless of whether the patient has diabetes [4, 5].

• Chronic Kidney Disease (CKD): Slowing kidney disease progression and reducing cardiovascular events in patients at risk of CKD progression, with or without diabetes [3].

2. Targeting the Hallmarks of Aging

The widespread organ protection delivered by SGLT2 inhibitors is driven by systemic metabolic and cellular reprogramming [1]. By altering energy availability and hemodynamic stress, SGLT2 inhibitors directly target several established Hallmarks of Aging [1, 7]:

Deregulated Nutrient Sensing

By inducing the urinary excretion of roughly 60 to 80 grams of glucose per day (equivalent to 240–320 kcal/day), SGLT2 inhibitors create a state of mild calorie restriction without actual dietary deprivation [1]. This mild caloric deficit downregulates nutrient-excess signaling (mTORC1) and upregulates energy-deprivation sensors: AMPK (adenosine monophosphate-activated protein kinase) and SIRT1 (sirtuin 1) [1].

Mitochondrial Dysfunction & Autophagy

The metabolic shift induced by SGLT2 inhibition increases low-level hepatic ketogenesis, raising circulating levels of beta-hydroxybutyrate [1]. Ketones serve as an energy-dense, "clean-burning" fuel for cardiac and renal mitochondria, reducing reactive oxygen species (ROS) production. Furthermore, AMPK and SIRT1 activation stimulates mitophagy—the targeted clearance and recycling of damaged mitochondria [1].

Altered Intercellular Communication & Inflammaging

Chronic, low-grade systemic inflammation (inflammaging) accelerates vascular and tissue degeneration. SGLT2 inhibitors consistently reduce circulating inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) [1, 3].

Cellular Senescence

Preclinical models demonstrate that by reducing tissue oxidative stress, downregulating mTORC1, and controlling metabolic inflammation, SGLT2 inhibitors exhibit senomorphic properties—suppressing the harmful Senescence-Associated Secretory Phenotype (SASP) secreted by senescent cells [1].

3. Preclinical Evidence: Lifespan Extension in the ITP

In preclinical geroscience, the gold standard for evaluating candidate longevity compounds is the National Institute on Aging’s Interventions Testing Program (ITP). The ITP tests candidate drugs in genetically heterogeneous mice across three independent research sites to ensure reproducibility.

In an ITP trial published by Miller et al., canagliflozin significantly extended median lifespan in male mice by 14%, alongside an increase in 90th-percentile survival (max lifespan) [2].

Interestingly, like several other nutrient-sensing interventions tested in the ITP, the lifespan extension was observed primarily in male mice, a sex difference thought to be linked to baseline differences in glucose handling and insulin sensitivity [2]. Subsequent preclinical studies have shown that SGLT2 inhibitors also preserve physical function, reduce age-related renal lesions, and improve vascular stiffness in aging rodents [1, 2].

4. Human Clinical Trial Evidence: Cardiorenal and Mortality Benefits

Unlike many candidate gerotherapeutics whose evidence rests entirely on preclinical models or small pilot studies, SGLT2 inhibitors possess extensive human clinical trial outcome data [1].

Landmark randomized controlled trials demonstrate profound, replicated reductions in hard clinical endpoints across diverse patient populations:

• The DAPA-HF Trial (Heart Failure with Reduced Ejection Fraction): Evaluated 4,744 patients with HFrEF. Dapagliflozin reduced the composite risk of cardiovascular death or worsening heart failure by 26% compared to placebo, with benefits occurring equally in patients with and without diabetes [4].

• The EMPEROR-Preserved Trial (Heart Failure with Preserved Ejection Fraction): Evaluated 5,988 patients with HFpEF. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization by 21%, filling a major therapeutic gap in cardiology [5].

• The DAPA-CKD & EMPA-KIDNEY Trials (Chronic Kidney Disease): Evaluated thousands of patients with established CKD. DAPA-CKD demonstrated a 39% reduction in the risk of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death [3].

These landmark trials confirm that SGLT2 inhibitors protect major organ systems through metabolic and hemodynamically protective pathways that function independently of blood sugar reduction [1, 3, 4].

5. What Studies Are Needed for Geromedicine?

Despite these impressive cardiorenal outcome data, critical research gaps remain before SGLT2 inhibitors can be definitively recommended as generalized gerotherapeutics for healthy, non-diabetic adults [1, 7].

To transition from a disease-specific treatment to an established healthspan intervention, the medical community requires:

1. Trials in Healthy, Non-Diabetic Older Adults: Existing human outcome trials enrolled patients with established Type 2 diabetes, heart failure, or chronic kidney disease [1]. Dedicated clinical trials are needed to evaluate whether SGLT2 inhibitors provide preventive healthspan benefits in healthy, non-diabetic individuals without baseline organ disease.

2. Geroscience-Specific Endpoints: Future trials must evaluate composite healthspan metrics—such as physical function batteries, cognitive performance, frailty index scores, and multimorbidity incidence—rather than relying solely on cardiovascular or renal disease events [1, 7].

3. Validation of Biomarker Changes: Tracking changes in composite biological age algorithms, senescent cell burden, and mitochondrial function parameters to confirm target engagement in human tissue [1, 7].

4. Long-Term Safety in Non-Diabetic Populations: While SGLT2 inhibitors are generally well-tolerated, rare risks—such as mycotic genital infections, euglycemic diabetic ketoacidosis (eDKA) during severe caloric restriction, and volume depletion—require careful monitoring, particularly in lean or active populations [1].

The Bottom Line

SGLT2 inhibitors represent one of the most promising bridges between modern cardiorenal medicine and translational geroscience [1]. By simulating calorie restriction, optimizing mitochondrial bioenergetics, reducing systemic inflammation, and protecting renal and cardiac vascular beds, SGLT2 inhibitors directly target key biological drivers of human aging [1, 3, 5].

For patients with elevated cardiometabolic risk, subclinical kidney dysfunction, or heart failure, SGLT2 inhibitors offer unmatched, evidence-based organ protection [1, 4]. As geroscience clinical trials progress, these agents may help pave the way toward proactive, mechanism-based healthspan extension.

Explore where candidate aging interventions stand on the clinical evidence spectrum using our free Gerotherapeutics Dashboard, or evaluate your broader physical and metabolic metrics with our Healthspan Engine.

(Disclosure: The Gerotherapeutics Dashboard and Healthspan Engine are free educational tools provided by delaeMD.)

References

1. Forman DE, Kuchel GA, Newman JC, et al. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Journal of the American College of Cardiology. 2023;82(7):631-647.

2. Miller RA, Harrison DE, Allison DB, et al. Canagliflozin extends lifespan in genetically heterogeneous male mice but not female mice. JCI Insight. 2020;5(21):e140019.

3. Heerspink HJL, Stefánsson BV, Chertow GM, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). The New England Journal of Medicine. 2020;383(15):1436-1446.

4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF). The New England Journal of Medicine. 2019;381(21):1995-2008.

5. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved). The New England Journal of Medicine. 2021;385(16):1451-1461.

6. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced). The New England Journal of Medicine. 2020;383(15):1413-1424.

7. Kritchevsky SB, Cummings SR. Geroscience. JAMA. 2025;334(12):1094-1102.